RenovaCare, Inc. (RCAR)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | - USD | -100.0% |
| 2021 | 1.3 Million USD | -0.91% |
| 2020 | 1.31 Million USD | 369.18% |
| 2019 | 280.74 Thousand USD | -28.5% |
| 2018 | 392.66 Thousand USD | -71.87% |
| 2017 | 1.39 Million USD | 283.5% |
| 2016 | 363.99 Thousand USD | 8.4% |
| 2015 | 335.78 Thousand USD | -11.42% |
| 2014 | 379.06 Thousand USD | 583.72% |
| 2013 | 55.44 Thousand USD | -43.47% |
| 2012 | 98.07 Thousand USD | -23.98% |
| 2011 | 129 Thousand USD | -97.58% |
| 2010 | 5.32 Million USD | 266.1% |
| 2009 | 1.45 Million USD | 2210.56% |
| 2008 | 62.93 Thousand USD | 150.6% |
| 2007 | 25.11 Thousand USD | -34.59% |
| 2006 | 38.39 Thousand USD | -1.94% |
| 2005 | 39.14 Thousand USD | 23.65% |
| 2004 | 31.66 Thousand USD | -9.88% |
| 2003 | 35.13 Thousand USD | -63.98% |
| 2002 | 97.52 Thousand USD | -48.88% |
| 2001 | 190.79 Thousand USD | 81.62% |
| 2000 | 105.04 Thousand USD | 406.85% |
| 1999 | 20.72 Thousand USD | 3.63% |
| 1998 | 20 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q2 | 2.68 Million USD | 22.96% |
| 2022 Q1 | 2.18 Million USD | 67.61% |
| 2022 FY | - USD | -100.0% |
| 2022 Q3 | 2.51 Million USD | -6.5% |
| 2022 Q4 | - USD | -100.0% |
| 2021 Q2 | 221.04 Thousand USD | -71.8% |
| 2021 FY | 1.3 Million USD | -0.91% |
| 2021 Q4 | 1.3 Million USD | 82.98% |
| 2021 Q3 | 713.31 Thousand USD | 222.71% |
| 2021 Q1 | 783.75 Thousand USD | -40.5% |
| 2020 Q3 | 804.15 Thousand USD | 0.86% |
| 2020 Q4 | 1.31 Million USD | 63.8% |
| 2020 FY | 1.31 Million USD | 369.18% |
| 2020 Q2 | 797.3 Thousand USD | 93.85% |
| 2020 Q1 | 411.29 Thousand USD | 46.51% |
| 2019 Q2 | 357.91 Thousand USD | -16.18% |
| 2019 Q4 | 280.74 Thousand USD | -41.82% |
| 2019 Q1 | 426.98 Thousand USD | 8.74% |
| 2019 Q3 | 482.56 Thousand USD | 34.83% |
| 2019 FY | 280.74 Thousand USD | -28.5% |
| 2018 Q1 | 1.29 Million USD | -7.48% |
| 2018 Q4 | 392.66 Thousand USD | -72.75% |
| 2018 Q3 | 1.44 Million USD | 10.05% |
| 2018 Q2 | 1.3 Million USD | 1.38% |
| 2018 FY | 392.66 Thousand USD | -71.87% |
| 2017 Q2 | 813.67 Thousand USD | 42.94% |
| 2017 Q4 | 1.39 Million USD | 25.72% |
| 2017 Q3 | 1.11 Million USD | 36.46% |
| 2017 Q1 | 569.23 Thousand USD | 56.39% |
| 2017 FY | 1.39 Million USD | 283.5% |
| 2016 Q3 | 251.32 Thousand USD | -5.51% |
| 2016 Q1 | 314.14 Thousand USD | -6.44% |
| 2016 Q2 | 265.98 Thousand USD | -15.33% |
| 2016 Q4 | 363.99 Thousand USD | 44.83% |
| 2016 FY | 363.99 Thousand USD | 8.4% |
| 2015 Q2 | 320.86 Thousand USD | -5.25% |
| 2015 Q3 | 347.34 Thousand USD | 8.25% |
| 2015 Q4 | 335.78 Thousand USD | -3.33% |
| 2015 FY | 335.78 Thousand USD | -11.42% |
| 2015 Q1 | 338.62 Thousand USD | -10.67% |
| 2014 Q2 | 126.41 Thousand USD | 100.42% |
| 2014 Q3 | 436.61 Thousand USD | 245.39% |
| 2014 FY | 379.06 Thousand USD | 583.72% |
| 2014 Q4 | 379.06 Thousand USD | -13.18% |
| 2014 Q1 | 63.07 Thousand USD | 13.77% |
| 2013 Q2 | 38.22 Thousand USD | -39.4% |
| 2013 FY | 55.44 Thousand USD | -43.47% |
| 2013 Q4 | 55.44 Thousand USD | -64.89% |
| 2013 Q1 | 63.07 Thousand USD | -35.69% |
| 2013 Q3 | 157.92 Thousand USD | 313.13% |
| 2012 Q3 | 115.9 Thousand USD | 9.68% |
| 2012 Q2 | 105.68 Thousand USD | 17.84% |
| 2012 Q4 | 98.07 Thousand USD | -15.39% |
| 2012 FY | 98.07 Thousand USD | -23.98% |
| 2012 Q1 | 89.68 Thousand USD | -30.48% |
| 2011 Q4 | 129 Thousand USD | -86.79% |
| 2011 Q2 | 2.31 Million USD | -56.67% |
| 2011 Q3 | 976.54 Thousand USD | -57.8% |
| 2011 FY | 129 Thousand USD | -97.58% |
| 2011 Q1 | 5.34 Million USD | 0.32% |
| 2010 Q2 | 1.4 Million USD | -58.33% |
| 2010 FY | 5.32 Million USD | 266.1% |
| 2010 Q4 | 5.32 Million USD | 1377.07% |
| 2010 Q3 | 360.39 Thousand USD | -74.39% |
| 2010 Q1 | 3.37 Million USD | 132.28% |
| 2009 Q3 | 703.35 Thousand USD | -68.56% |
| 2009 Q1 | 65.57 Thousand USD | 4.2% |
| 2009 FY | 1.45 Million USD | 2210.56% |
| 2009 Q2 | 2.23 Million USD | 3311.77% |
| 2009 Q4 | 1.45 Million USD | 106.73% |
| 2008 Q3 | 9643.00 USD | -62.56% |
| 2008 FY | 62.93 Thousand USD | 150.6% |
| 2008 Q4 | 62.93 Thousand USD | 552.61% |
| 2008 Q1 | 25.8 Thousand USD | 2.76% |
| 2008 Q2 | 25.75 Thousand USD | -0.18% |
| 2007 Q2 | 32.9 Thousand USD | -14.08% |
| 2007 FY | 25.11 Thousand USD | -34.59% |
| 2007 Q1 | 38.29 Thousand USD | -0.24% |
| 2007 Q4 | 25.11 Thousand USD | -15.81% |
| 2007 Q3 | 29.82 Thousand USD | -9.37% |
| 2006 Q4 | 38.39 Thousand USD | 2.07% |
| 2006 FY | 38.39 Thousand USD | -1.94% |
| 2006 Q1 | 28.67 Thousand USD | -26.75% |
| 2006 Q2 | 30.81 Thousand USD | 7.46% |
| 2006 Q3 | 37.61 Thousand USD | 22.07% |
| 2005 Q3 | 28.86 Thousand USD | 19.0% |
| 2005 FY | 39.14 Thousand USD | 23.65% |
| 2005 Q4 | 39.14 Thousand USD | 35.64% |
| 2005 Q2 | 24.25 Thousand USD | 0.83% |
| 2005 Q1 | 24.05 Thousand USD | -24.03% |
| 2004 Q4 | 31.66 Thousand USD | 3.12% |
| 2004 FY | 31.66 Thousand USD | -9.88% |
| 2004 Q2 | 30.46 Thousand USD | 0.79% |
| 2004 Q1 | 30.22 Thousand USD | -13.97% |
| 2004 Q3 | 30.7 Thousand USD | 0.79% |
| 2003 Q2 | 42.07 Thousand USD | -1.88% |
| 2003 Q3 | 59.11 Thousand USD | 40.5% |
| 2003 Q4 | 35.13 Thousand USD | -40.57% |
| 2003 FY | 35.13 Thousand USD | -63.98% |
| 2003 Q1 | 42.88 Thousand USD | -56.03% |
| 2002 Q3 | 261.49 Thousand USD | -2.61% |
| 2002 FY | 97.52 Thousand USD | -48.88% |
| 2002 Q4 | 97.52 Thousand USD | -62.7% |
| 2002 Q1 | 221.85 Thousand USD | 16.28% |
| 2002 Q2 | 268.49 Thousand USD | 21.02% |
| 2001 Q2 | 158.43 Thousand USD | 12.54% |
| 2001 Q1 | 140.77 Thousand USD | 34.01% |
| 2001 Q3 | 119.5 Thousand USD | -24.57% |
| 2001 Q4 | 190.79 Thousand USD | 59.66% |
| 2001 FY | 190.79 Thousand USD | 81.62% |
| 2000 Q2 | 30.39 Thousand USD | -6.08% |
| 2000 FY | 105.04 Thousand USD | 406.85% |
| 2000 Q3 | 26.67 Thousand USD | -12.24% |
| 2000 Q4 | 105.04 Thousand USD | 293.77% |
| 2000 Q1 | 32.36 Thousand USD | 0.0% |
| 1999 FY | 20.72 Thousand USD | 3.63% |
| 1998 FY | 20 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 100.0% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 5.24 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 100.0% |
| Qrons Inc. | 1.48 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 1.22 Million USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 14.07 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 50.03 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 12 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 100.0% |
| Mesoblast Limited | 188.44 Million USD | 100.0% |
| Marizyme, Inc. | 26.67 Million USD | 100.0% |
| Genus plc | 485 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 100.0% |
| Pharming Group N.V. | 244.07 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 100.0% |
| ContraFect Corporation | 32.53 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 100.0% |
| IMV Inc. | 37.93 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 1617.67 USD | 100.0% |
| ONE Bio Corp. | 27.49 Million USD | 100.0% |
| Accustem Sciences Inc. | 1.07 Million USD | 100.0% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 2.11 Million USD | 100.0% |
| Q BioMed Inc. | 8.13 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 100.0% |
| Biomind Labs Inc. | 1.49 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 100.0% |
| GB Sciences, Inc. | 5.41 Million USD | 100.0% |
| Alpha Cognition Inc. | 7.16 Million USD | 100.0% |
| HST Global, Inc. | 593.59 Thousand USD | 100.0% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 100.0% |
| Halberd Corporation | 728.71 Thousand USD | 100.0% |
| Enzolytics Inc. | 365.26 Million USD | 100.0% |
| Agentix Corp. | 2.51 Million USD | 100.0% |
| Resverlogix Corp. | 67.39 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 444.95 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 100.0% |
| AVAX Technologies, Inc. | 3.99 Million USD | 100.0% |
| Zenith Capital Corp. | 27.56 Thousand USD | 100.0% |
| Genscript Biotech Corporation | 1.32 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 100.0% |
| Kadimastem Ltd | 3.5 Million USD | 100.0% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 100.0% |
| BioStem Technologies, Inc. | 15.9 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 100.0% |
| LadRx Corporation | 2.2 Million USD | 100.0% |
| Cell Source, Inc. | 15.8 Million USD | 100.0% |
| Regen BioPharma, Inc. | 5.45 Million USD | 100.0% |
| Regen BioPharma, Inc. | 5.45 Million USD | 100.0% |
| NovAccess Global Inc. | 7.86 Million USD | 100.0% |
| Affymax, Inc. | 8.87 Million USD | 100.0% |
| Itoco Inc. | 1.65 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 100.0% |
| Mobile Lads Corp. | 1.31 Million USD | 100.0% |
| CytoDyn Inc. | 127.89 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 100.0% |
| SYBLEU INC | 681.41 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 100.0% |
| International Stem Cell Corporation | 5.27 Million USD | 100.0% |
| Bioxytran, Inc. | 3.24 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 4.61 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 40.99 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 100.0% |
| Regnum Corp. | 2.02 Million USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 100.0% |
| Neutra Corp. | 973.52 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 100.0% |
| PureTech Health plc | 125.58 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 100.0% |
| IXICO plc | 1.9 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 100.0% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 100.0% |